NCT06163781 Appropriate Use of Blood Cultures in the Emergency Department Through Machine Learning
| NCT ID | NCT06163781 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Amsterdam UMC, location VUmc |
| Condition | Artificial Intelligence |
| Study Type | INTERVENTIONAL |
| Enrollment | 7,584 participants |
| Start Date | 2024-02-19 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 7,584 participants in total. It began in 2024-02-19 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to study whether the use of our blood culture prediction tool is non-inferior to current practice and if it can improve certain outcomes in all adult patients presenting to the emergency department with a clinical indication for a blood culture analysis (according to the treating physician). The primary endpoint is 30-day mortality. Key secondary outcomes are: * hospital admission rates * in-hospital mortality * hospital length-of-stay. In the intervention group, the physician will follow the advice of our blood culture prediction tool. In the comparison group all patients will undergo a blood culture analysis.
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years * Have a clinical indication for a blood culture analysis (according to the treating physician) * Have sufficient data recorded (laboratory results and vital sign measurements) for a prediction to be made (at least 20% of the needed parameters) Exclusion Criteria: * Central Venous Line (CVL) or Peripherally Inserted Central Catheter (PICC) in situ * Neutrophil count \< 0.5 \* 109/L * Candidemia or S. aureus bacteraemia in the past 3 months. * Most likely diagnosis of endocarditis/spondylodiscitis/infected prosthetic material * Pregnant or breastfeeding patients * Not capable of giving informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06163781 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Artificial Intelligence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06163781 currently recruiting?
Yes, NCT06163781 is actively recruiting participants. Contact the research team at p.nanayakkara@amsterdamumc.nl for enrollment information.
Where is the NCT06163781 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands.
Who is sponsoring the NCT06163781 clinical trial?
NCT06163781 is sponsored by Amsterdam UMC, location VUmc. The trial plans to enroll 7,584 participants.